[{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Topical","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Revive Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Corvidia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"D6PV","moa":"Apolipoprotein C-III","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Corvidia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Corvidia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Corvidia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Inositec AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"INS-3001","moa":"Vascular calcification","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Inositec AG","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Inositec AG \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Inositec AG \/ Not Applicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Neurokinin 1 receptor positive mesenchymal stem cell","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioCardia \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BioCardia \/ Not Applicable"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"AAV-Gene Therapy","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Tenaya Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tenaya Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Verve Therapeutics","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Series A Financing","leadProduct":"Gene-editing therapies","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Verve Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Verve Therapeutics \/ ARCH Venture Partners","highestDevelopmentStatusID":"4","companyTruncated":"Verve Therapeutics \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Primary Peptides","sponsor":"Simcere Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Peptide","year":"2020","type":"Partnership","leadProduct":"PP-001","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Primary Peptides","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Primary Peptides \/ Simcere Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Primary Peptides \/ Simcere Pharmaceutical"},{"orgOrder":0,"company":"Primary Peptides","sponsor":"Qingdao Primedicine Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Peptide","year":"2020","type":"Licensing Agreement","leadProduct":"PP-002","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Primary Peptides","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Primary Peptides \/ Qingdao Primedicine Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Primary Peptides \/ Qingdao Primedicine Pharmaceutical"},{"orgOrder":0,"company":"Nyrada","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"NYX-PCSK9i","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Nyrada","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nyrada \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nyrada \/ Not Applicable"},{"orgOrder":0,"company":"Vivasc Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"CTP-Amio","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Vivasc Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Vivasc Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Vivasc Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Dogma Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Dogma Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dogma Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"Dogma Therapeutics \/ AstraZeneca"},{"orgOrder":0,"company":"AnaBios","sponsor":"Orion Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"ORM-11372","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"AnaBios","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"AnaBios \/ Orion","highestDevelopmentStatusID":"4","companyTruncated":"AnaBios \/ Orion"},{"orgOrder":0,"company":"Saillant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"ST02","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Saillant Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Saillant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Saillant Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Serometrix","sponsor":"Esperion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Serometrix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Serometrix \/ ESPERION","highestDevelopmentStatusID":"4","companyTruncated":"Serometrix \/ ESPERION"},{"orgOrder":0,"company":"Indication BioScience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Atorvastatin","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Indication BioScience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Indication BioScience \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Indication BioScience \/ Not Applicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Precision BioSciences \/ Not Applicable"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"MCB-613","moa":"Steroid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Baylor College of Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Baylor College of Medicine \/ Not Applicable"},{"orgOrder":0,"company":"CMAX","sponsor":"Claritas Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Nitric oxide-releasing compound","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"CMAX","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CMAX \/ Claritas","highestDevelopmentStatusID":"4","companyTruncated":"CMAX \/ Claritas"},{"orgOrder":0,"company":"Shifa Biomedical","sponsor":"Xontogeny, LLC","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2021","type":"Financing","leadProduct":"P-21","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Shifa Biomedical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shifa Biomedical \/ Xontogeny, LLC","highestDevelopmentStatusID":"4","companyTruncated":"Shifa Biomedical \/ Xontogeny, LLC"},{"orgOrder":0,"company":"PulmoSIM Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2021","type":"Not Applicable","leadProduct":"PT001","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"PulmoSIM Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"PulmoSIM Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PulmoSIM Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"TATX-21","moa":"LDL uptake","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"ImmunoPrecise","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"ImmunoPrecise \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ImmunoPrecise \/ Not Applicable"},{"orgOrder":0,"company":"Nuevocor","sponsor":"EVX Ventures","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Series A Financing","leadProduct":"AAV-based Gene Therapy","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Nuevocor","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.02,"dosageForm":"","sponsorNew":"Nuevocor \/ EVX Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Nuevocor \/ EVX Ventures"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"TYA-11631","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Tenaya Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tenaya Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"TATX-21","moa":"LDL uptake","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"ImmunoPrecise","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"ImmunoPrecise \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ImmunoPrecise \/ Not Applicable"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Lexeo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Acquisition","leadProduct":"LX2022","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Lexeo Therapeutics \/ LEXEO Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lexeo Therapeutics \/ LEXEO Therapeutics"},{"orgOrder":0,"company":"AgeX Therapeutics","sponsor":"Lygenesis","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Termination","leadProduct":"AGEX-VASC1","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"AgeX Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"AgeX Therapeutics \/ LyGenesis","highestDevelopmentStatusID":"4","companyTruncated":"AgeX Therapeutics \/ LyGenesis"},{"orgOrder":0,"company":"Gubra","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Peptide","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Gubra","amount2":0.25,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.25,"dosageForm":"","sponsorNew":"Gubra \/ Bayer AG","highestDevelopmentStatusID":"4","companyTruncated":"Gubra \/ Bayer AG"},{"orgOrder":0,"company":"Ambulero","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"AMB-301","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Ambulero","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Ambulero \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ambulero \/ Not Applicable"},{"orgOrder":0,"company":"XBiotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"CAR90972","moa":"IL-1 alpha","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"XBiotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"XBiotech \/ Not Applicable"},{"orgOrder":0,"company":"Imara","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tovinontrine","moa":"PDE9","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Imara","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Imara \/ Not Applicable"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"DCR-NOVO1","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Dicerna Pharmaceuticals","amount2":3.2999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":3.2999999999999998,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Dicerna Pharmaceuticals \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"Dicerna Pharmaceuticals \/ Novo Nordisk"},{"orgOrder":0,"company":"Ceapro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Beta Glucan","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Ceapro","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ceapro \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ceapro \/ Not Applicable"},{"orgOrder":0,"company":"Institute of Materia Medica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bilobalide","moa":"Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Institute of Materia Medica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Institute of Materia Medica \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Institute of Materia Medica \/ Not Applicable"},{"orgOrder":0,"company":"Elastrin Therapeutics","sponsor":"Kizoo Technology Capital","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2022","type":"Financing","leadProduct":"ELT-001","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Elastrin Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"Elastrin Therapeutics \/ Kizoo Technology Capital","highestDevelopmentStatusID":"4","companyTruncated":"Elastrin Therapeutics \/ Kizoo Technology Capital"},{"orgOrder":0,"company":"HAYA Therapeutics","sponsor":"Innosuisse","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2022","type":"Funding","leadProduct":"HTX-001","moa":"IncRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"HAYA Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"HAYA Therapeutics \/ Innosuisse","highestDevelopmentStatusID":"4","companyTruncated":"HAYA Therapeutics \/ Innosuisse"},{"orgOrder":0,"company":"HAYA Therapeutics","sponsor":"Broadview Ventures","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2021","type":"Financing","leadProduct":"HTX-001","moa":"IncRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"HAYA Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.02,"dosageForm":"","sponsorNew":"HAYA Therapeutics \/ Broadview Ventures","highestDevelopmentStatusID":"4","companyTruncated":"HAYA Therapeutics \/ Broadview Ventures"},{"orgOrder":0,"company":"Renovacor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"AAV-based Gene Therapy","moa":"BAG3 Gene","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Renovacor","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Renovacor \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Renovacor \/ Not Applicable"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"TN-201","moa":"MYBPC3 Gene","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Tenaya Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tenaya Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Advanced NanoTherapies","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Series A Financing","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Advanced NanoTherapies","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Advanced NanoTherapies \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Advanced NanoTherapies \/ Undisclosed"},{"orgOrder":0,"company":"GB Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"GB Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"GB Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"GB Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Orchestra Biomed","sponsor":"Terumo","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Orchestra Biomed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Orchestra Biomed \/ Terumo","highestDevelopmentStatusID":"4","companyTruncated":"Orchestra Biomed \/ Terumo"},{"orgOrder":0,"company":"Renovacor","sponsor":"University of Utah\u2019s Nora Eccles Harrison Cardiovascular Research and Training Institute","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"AAV-based Gene Therapy","moa":"DSG2 gene","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Renovacor","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Renovacor \/ University of Utah\u2019s Nora Eccles Harrison Cardiovascular Research and Training Institute","highestDevelopmentStatusID":"4","companyTruncated":"Renovacor \/ University of Utah\u2019s Nora Eccles Harrison Cardiovascular Research and Training Institute"},{"orgOrder":0,"company":"Humacyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Human Acellular Vessels","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Humacyte \/ Not Applicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Human Acellular Vessel","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Humacyte \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Humacyte \/ Not Applicable"},{"orgOrder":0,"company":"Lexaria Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Lexaria Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Lexaria Bioscience \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lexaria Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"STP135G","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sirnaomics \/ Not Applicable"},{"orgOrder":0,"company":"Forcefield Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Chrdl1","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Forcefield Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Forcefield Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Forcefield Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Gatehouse Bio","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2022","type":"Partnership","leadProduct":"GHB-002","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Gatehouse Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Gatehouse Bio \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"Gatehouse Bio \/ AstraZeneca"},{"orgOrder":0,"company":"Cereno Scientific","sponsor":"University of Michigan","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"CS585","moa":"Prostacyclin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Cereno Scientific","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Cereno Scientific \/ University of Michigan","highestDevelopmentStatusID":"4","companyTruncated":"Cereno Scientific \/ University of Michigan"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Cardiol Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cardiol Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Renovacor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"AAV-based Gene Therapy","moa":"BAG3 Gene","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Renovacor","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Renovacor \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Renovacor \/ Not Applicable"},{"orgOrder":0,"company":"Nuevocor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Recombinant Adeno-associated Virus Based Gene Therapy","moa":"LMNA Gene","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Nuevocor","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Nuevocor \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nuevocor \/ Not Applicable"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"University of Michigan School","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"SOD2 mRNA Therapeutic","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Altamira Therapeutics \/ University of Michigan School","highestDevelopmentStatusID":"4","companyTruncated":"Altamira Therapeutics \/ University of Michigan School"},{"orgOrder":0,"company":"Renovacor","sponsor":"Rocket Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Acquisition","leadProduct":"REN-001","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Renovacor","amount2":0.050000000000000003,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"Renovacor \/ Rocket Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Renovacor \/ Rocket Pharmaceuticals"},{"orgOrder":0,"company":"Nuevocor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Recombinant AAV\u2011based Gene Therapy","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Nuevocor","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Nuevocor \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nuevocor \/ Not Applicable"},{"orgOrder":0,"company":"Orchestra Biomed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sirolimus","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Orchestra Biomed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Orchestra Biomed \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Orchestra Biomed \/ Not Applicable"},{"orgOrder":0,"company":"Amplifier Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"ATX-304","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Amplifier Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Amplifier Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Amplifier Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Forcefield Therapeutics","sponsor":"Spur Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"AAV-based Gene Therapy","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Forcefield Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Forcefield Therapeutics \/ Freeline Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Forcefield Therapeutics \/ Freeline Therapeutics"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Anavex Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Mesenchymal Stem Cell","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"BioCardia \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BioCardia \/ Not Applicable"},{"orgOrder":0,"company":"Closed Loop Medicine","sponsor":"Pharmanovia","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Closed Loop Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Closed Loop Medicine \/ Pharmanovia","highestDevelopmentStatusID":"4","companyTruncated":"Closed Loop Medicine \/ Pharmanovia"},{"orgOrder":0,"company":"Verve Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Lipoprotein","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Verve Therapeutics","amount2":0.53000000000000003,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.53000000000000003,"dosageForm":"","sponsorNew":"Verve Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Verve Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"ZYMEDI","sponsor":"National Heart, Lung, and Blood Institute","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"ZMA001","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"ZYMEDI","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ZYMEDI \/ National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"4","companyTruncated":"ZYMEDI \/ National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Heqet Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Genetic Medicine","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Altamira Therapeutics \/ Heqet Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Altamira Therapeutics \/ Heqet Therapeutics"},{"orgOrder":0,"company":"Riparian Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Riparian Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Riparian Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"4","companyTruncated":"Riparian Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Riparian Pharmaceuticals","sponsor":"Viva Biotech","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Riparian Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Riparian Pharmaceuticals \/ Viva Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Riparian Pharmaceuticals \/ Viva Biotech"},{"orgOrder":0,"company":"Orchestra Biomed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sirolimus","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Orchestra Biomed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Orchestra Biomed \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Orchestra Biomed \/ Not Applicable"},{"orgOrder":0,"company":"Advanced NanoTherapies","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2023","type":"Series A Financing","leadProduct":"Sirolimus","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Advanced NanoTherapies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Advanced NanoTherapies \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Advanced NanoTherapies \/ Undisclosed"},{"orgOrder":0,"company":"Epigenic Therapeutics","sponsor":"Qiming Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Epigenic Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Epigenic Therapeutics \/ Qiming Venture Partners","highestDevelopmentStatusID":"4","companyTruncated":"Epigenic Therapeutics \/ Qiming Venture Partners"},{"orgOrder":0,"company":"AMO Pharma","sponsor":"Population Health Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Tideglusib","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"AMO Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"AMO Pharma \/ Population Health Research Institute","highestDevelopmentStatusID":"4","companyTruncated":"AMO Pharma \/ Population Health Research Institute"},{"orgOrder":0,"company":"IsomAb","sponsor":"Broadview Ventures","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2024","type":"Financing","leadProduct":"ISM-001","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"IsomAb","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"IsomAb \/ Broadview Ventures","highestDevelopmentStatusID":"4","companyTruncated":"IsomAb \/ Broadview Ventures"},{"orgOrder":0,"company":"Celanese","sponsor":"Secarna Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Celanese","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Sustained-Release Implant","sponsorNew":"Celanese \/ Secarna Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Celanese \/ Secarna Pharma"},{"orgOrder":0,"company":"BioCardia","sponsor":"StemCardia","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"SCM-102","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"BioCardia \/ StemCardia","highestDevelopmentStatusID":"4","companyTruncated":"BioCardia \/ StemCardia"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"CAN10","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cantargia AB \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cantargia AB \/ Not Applicable"},{"orgOrder":0,"company":"Elastin BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Elastin BioSciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Elastin BioSciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Elastin BioSciences \/ Not Applicable"},{"orgOrder":0,"company":"Anew Medical","sponsor":"Japan\u2019s Okinawa Research Center","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"Klotho Gene Therapy","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Anew Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Anew Medical \/ Japan\u2019s Okinawa Research Center","highestDevelopmentStatusID":"4","companyTruncated":"Anew Medical \/ Japan\u2019s Okinawa Research Center"}]
Find Drugs for Cardiology/Vascular Diseases in Preclinical Development
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
